Biejia-Ruangan compound and incidence of hepatocellular carcinoma
- PMID: 36402448
- DOI: 10.1016/j.jhep.2022.11.012
Biejia-Ruangan compound and incidence of hepatocellular carcinoma
Comment in
-
Reply to: "Biejia-Ruangan compound and incidence of hepatocellular carcinoma".J Hepatol. 2023 Apr;78(4):e142-e144. doi: 10.1016/j.jhep.2023.01.003. Epub 2023 Jan 13. J Hepatol. 2023. PMID: 36646213 No abstract available.
Comment on
-
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.J Hepatol. 2022 Dec;77(6):1515-1524. doi: 10.1016/j.jhep.2022.07.018. Epub 2022 Aug 18. J Hepatol. 2022. PMID: 35985545 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical